The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.

Details

Ressource 1Download: serval:BIB_2303.P001 (188.46 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_2303
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Journal
American Journal of Hypertension
Author(s)
Brunner H.R.
ISSN
0895-7061
Publication state
Published
Issued date
1997
Volume
10
Number
12 Pt 2
Pages
311S-317S
Language
english
Notes
Publication types: Journal Article ; Review
Abstract
This article reviews the pharmacokinetics and pharmacodynamics of angiotensin II (AII) receptor antagonists (AIIRA), with particular focus on the novel compound irbesartan. Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food. Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h). Irbesartan exhibits the lowest amount of protein binding, limiting its potential for drug interactions. No drug interactions with irbesartan have been identified. Unlike losartan, candesartan, and tasosartan, irbesartan does not require biotransformation for AII blockade. The pharmacokinetics of irbesartan are not altered in renally or hepatically impaired patients, probably owing to excretion characteristic by both biliary and renal routes, or by differences in gender or age. Within its therapeutic dose range (150 to 300 mg), irbesartan shows sustained, dose related blockade 24 h after dosing. Irbesartan lowers blood pressure in a dose related manner up to 300 mg daily. Some clear differences in pharmacokinetics and pharmacodynamics exist among the AIIRA, which may have clinical implications.
Keywords
Antihypertensive Agents/pharmacokinetics, Biphenyl Compounds/pharmacokinetics, Biphenyl Compounds/pharmacology, Drug Interactions, Humans, Hypertension/drug therapy, Kidney Diseases/metabolism, Liver Diseases/metabolism, Receptors, Angiotensin/antagonists &amp, inhibitors, Tetrazoles/pharmacokinetics, Tetrazoles/pharmacology
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2007 12:18
Last modification date
01/10/2019 6:17
Usage data